Sodium glucose cotransporter 2 inhibitors.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  The Medical clinics of North America

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.mcna.2014.08.020PMID 25456647
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• SGLT2 inhibitors in the treatment of type 2 diabetes.

  2014cited by this paper
• Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus

  2014cited by this paper
• Drug–Drug Interactions with Sodium-Glucose Cotransporters Type 2 (SGLT2) Inhibitors, New Oral Glucose-Lowering Agents for the Management of Type 2 Diabetes Mellitus

  2014cited by this paper
• Sodium glucose transport 2 (SGLT2) inhibition decreases glomerular hyperfiltration: is there a role for SGLT2 inhibitors in diabetic kidney disease?

  2014cited by this paper
• Effect of canagliflozin, a sodium–glucose cotransporter 2 inhibitor, on measurement of serum 1,5‐anhydroglucitol (坎格列净，一种钠‐葡萄糖共转运体2抑制剂，对血清1,5‐脱水葡萄糖醇测定的影响)

  2014cited by this paper
• Empagliflozin improves glycaemic and weight control as add‐on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24‐week, randomized, placebo‐controlled trial

  2014cited by this paper
• Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial

  2014cited by this paper
• SGLT-2 Inhibitors: A New Mechanism for Glycemic Control

  2014cited by this paper
• Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment

  2014cited by this paper
• Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes

  2013cited by this paper
• Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin.

  2013cited by this paper
• Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes.

  2013cited by this paper
• Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.

  2013cited by this paper
• Urinary tract infections in patients with diabetes treated with dapagliflozin.

  2013cited by this paper
• Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy

  2012cited by this paper
• LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a Randomized, Placebo-Controlled Trial

  2012cited by this paper
• Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.

  2012cited by this paper
• The proximal tubule in the pathophysiology of the diabetic kidney.

  2011cited by this paper
• An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function.

  2011cited by this paper
• Apple Trees to Sodium Glucose Co-Transporter Inhibitors: A Review of SGLT2 Inhibition

  2010cited by this paper
• Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications.

  2009cited by this paper
• Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes.

  2005cited by this paper
• A Novel Role for Glucose 6-Phosphatase in the Small Intestine in the Control of Glucose Homeostasis*

  2004cited by this paper
• Renal substrate exchange and gluconeogenesis in normal postabsorptive humans.

  2002cited by this paper
• Renal gluconeogenesis: its importance in human glucose homeostasis.

  2001cited by this paper
• Renal Na(+)-glucose cotransporters.

  2001cited by this paper
• Renal glucose threshold variations with age.

  1967cited by this paper
• Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose.

  1951cited by this paper

• SGLT2 inhibitors in hemodialysis or peritoneal dialysis patients: rationale and state-of-the art

  2025cites this paper
• Effects and safety of dapagliflozin in paediatric hereditary kidney disease: protocol for a multicentric, prospective, open and randomised crossover study (DAPA-PedHKD)

  2025cites this paper
• Volume 16

  2025cites this paper
• SGLT2 Inhibitors and genital infections: a prospective observational study in a tertiary care hospital

  2025cites this paper
• Development and optimization of dapagliflozin oral nano-bilosomes using response surface method: in vitro evaluation, in vivo evaluation

  2025cites this paper
• The effects of sodium-glucose cotransporters type 2 inhibitors on glycemic and extraglycemic laboratory parameters

  2024cites this paper
• Subject Index Volume 14

  2023cites this paper
• SIMPLE QUANTIFIED AND VALIDATED STABILITY INDICATING STRESS DEGRADATION STUDIES OF ORAL ANTI-DIABETIC AGENT DAPAGLIFLOZIN BY RP-HPLC METHOD

  2022cites this paper
• Effects of empagliflozin on markers of calcium and phosphate homeostasis in patients with type 2 diabetes – Data from a randomized, placebo-controlled study

  2022cites this paper
• Is the Risk of Diabetes Lower in Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulant Compared to Warfarin?

  2022cites this paper
• INDEX

  2022cites this paper
• Sodium-Glucose Co-transporter-2 Inhibitors and Nephroprotection in Diabetic Patients: More Than a Challenge

  2021cites this paper
• Sodium Transporters in Human Health and Disease

  2021cites this paper
• Epigenetic modification and therapeutic targets of diabetes mellitus

  2020cites this paper
• In response to Yaribeygi et al. "Sodium‐glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways"

  2019cites this paper
• Formulation of Dapagliflozin and Saxagliptin Tablets and In vitro Evaluation by RP-HPLC Method

  2019cites this paper
• New hypoglycemic agents and the kidney: what do the major trials tell us?

  2018cites this paper
• Associations of Insulin Levels and Insulin Resistance With Urine Glucose Excretion Independent of Blood Glucose in Chinese Adults With Prediabetes and Newly Diagnosed Diabetes

  2018cites this paper
• Long‐term mono‐ or dual‐combination empagliflozin treatment for adults with type 2 diabetes mellitus

  2018cites this paper
• Development and Validation of a New HPLC Method for the Simultaneous Estimation of Saxagliptine and Dapagliflozin and Its Application in Pharmacokinetic Studies

  2018cites this paper
• DEVELOPMENT OF A NEW STABILITY INDICATING RP-HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF SAXAGLIPTINE AND DAPAGLIFLOZIN AND ITS VALIDATION AS PER ICH GUIDELINES

  2017cites this paper
• In Vitro Dissolution Profile of Dapagliflozin: Development, Method Validation, and Analysis of Commercial Tablets

  2017cites this paper
• SGLT2 inhibitors.

  2016cites this paper
• Overview of Sodium-Glucose Co-Transport Inhibitors

  2015influential citation